New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

New data reveals long-term benefit of adjuvant therapy for Stage III melanoma.

3 September 2020

Updated results published today in the prestigious New England Journal of Medicine herald the long-term effectiveness of a targeted combination drug therapy given after surgery in patients with high risk early melanoma.

The international study reports that in patients with Stage III BRAF-positive melanoma who were treated with adjuvant targeted therapy, there can be a long-lasting benefit from the treatment in preventing the disease from recurring.

In the Phase III trial, known as COMBI-AD, patients were treated with either a combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) or placebo given after surgery. The trial demonstrated early promising results after 12 months of treatment and significantly improved recurrence-free survival.

This latest publication revealed the effects of treatment have continued to be sustained after five years. In patients who received the combination therapy, 52% had no disease recurrence after five years. By comparison, only 36% of those patients on placebo – which was the standard of care at the time - had no disease recurrence during this time.

“Our research has demonstrated that many patients have long-term benefit on adjuvant combination targeted therapy, and it may be curative in most of those patients,” says co-senior author and Co-Medical Director of Melanoma Institute Australia Professor Georgina Long AO.

The study shows that adjvuant targeted therapy for patients with the BRAF mutation prevents recurrence in high-risk stage III melanoma.

“Melanoma Institute Australia is working closely with our international collaborators to take major steps forward in cancer treatment,” says Professor Long. “These results take us even closer to reaching our goal of zero deaths from melanoma this decade.”

 

Journal publication:

Reinhard Dummer, M.D., Axel Hauschild, M.D.,Mario Santinami, M.D., Victoria Atkinson, M.D., Mario Mandalà, M.D., John M. Kirkwood, M.D., Vanna Chiarion Sileni, M.D., James Larkin, M.D., Ph.D., Marta Nyakas, M.D., Caroline Dutriaux, M.D., Andrew Haydon, M.B., B.S., Ph.D., Caroline Robert, M.D., Ph.D., Laurent Mortier, M.D., Ph.D., Jacob Schachter, .D., Thierry Lesimple, M.D., Ruth Plummer, M.D., Kohinoor Dasgupta, Ph.D., Eduard Gasal, M.D., Monique Tan, M.D., Georgina V. Long, M.B., B.S., Ph.D., and Dirk Schadendorf, M.D.

(2020) Five-Year Relapse-Free Survival With Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutant Melanoma. NEJM. 

Read online here

Global Melanoma Research Report - July
20 Jul 2017

Global Melanoma Research Report - July

In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.

A day in the life of... Sarah Lane
14 Jul 2017

A day in the life of... Sarah Lane

Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process. 

Differentiating moles from melanoma
14 Jul 2017

Differentiating moles from melanoma

Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.

Introducing SunSense Sunscreen
11 Jul 2017

Introducing SunSense Sunscreen

We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business. 

Identifying hidden melanoma
07 Jul 2017

Identifying hidden melanoma

New MIA research revealed dermoscopy features that can help detect desmoplastic melanoma.

60 Minutes' MIA Patient Feature Program
04 Jul 2017

60 Minutes' MIA Patient Feature Program

Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here

Training our future melanoma experts
22 Jun 2017

Training our future melanoma experts

Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.

Update from ASCO 2017
17 Jun 2017

Update from ASCO 2017

Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.

Diagnosing melanoma of the mouth
16 Jun 2017

Diagnosing melanoma of the mouth

MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.

New practice-changing research will reduce the need for major surgery in many melanoma patients
09 Jun 2017

New practice-changing research will reduce the need for major surgery in many melanoma patients

New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.

MIA researchers to share new findings at world's largest cancer conference
25 May 2017

MIA researchers to share new findings at world's largest cancer conference

Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
18 May 2017

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.

Melanoma March 2017 wraps up!
12 May 2017

Melanoma March 2017 wraps up!

Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen. 

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
11 May 2017

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!

Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!

Whole genome sequencing finds unexpected genomic landscape in melanoma
10 May 2017

Whole genome sequencing finds unexpected genomic landscape in melanoma

By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.

Shining a light on melanomas that aren't caused by the sun
04 May 2017

Shining a light on melanomas that aren't caused by the sun

‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.

New research which more accurately predicts survival for melanoma patients
19 Apr 2017

New research which more accurately predicts survival for melanoma patients

Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.

Celebrating 60 years of melanoma research to save lives
19 Apr 2017

Celebrating 60 Years of melanoma research to save lives

MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.

Celebrating our research achievements
07 Apr 2017

Celebrating our research achievements

Research achievements by MIA were celebrated at the annual Sydney Medical School recently.

Global Melanoma Research Report - April
06 Apr 2017

Global Melanoma Research Report - April

In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.